Endocrine Abstracts

In patients with type 2 diabetes mellitus (T2DM), cardiovascular lesions are 3–4 times more often than in non-diabetics. Screening for T2DM in 1564 people from all Ukraine revealed that 12% had HbA1c at 6.1–6.4% and 16% had HbA1c above 6.5%. Those with HbA1c above 6.5% were examined for BMI, glycemia, total cholesterol, HDL-C, non-HDL-C. Dyslipidemia was defined as total cholesterol over 5.20 mmol/l, HDL-C – less than 1.02 mmol/l for males and less than 1.29 mmol/l for females. Total cholesterol averaged 6.41±0.03 mmol/l in screened men and 6.23±0.01 in women. HDL-C was respectively 1.89±0.08 and 1.88±0.07 mmol/l. Whereas non-HDL-C was 4.60±0.02 and 3.38±0.05 mmol/l respectively. As for total cholesterol, objects were divided into the following groups (in mmol/l): 5.2; 5.3–6.5 and over 6.5. Males with these indicators were distributed: 38%, 57%, 5%; females – 28%, 64% and 8% respectively. According to correlation of total cholesterol to fasting glucose, men with glycemia under 6.1 mmol/l had cholesterol 5.70±0.01 mmol/l, those with glycemia 6.2–7.8 mmol/l had cholesterol 5.90±0.05 mmol/l and those with glycemia over 7.8 mmol/l had cholesterol 5.99±0.04 mmol/l. While in women, cholesterol levels were (mmol/l): 4.86±0.03, 6.50±0.03, and 7.50±0.03 in relation to the above mentioned levels of glycemia. In accordance with division of BMI into normal weight, overweight and obesity, cholesterol levels in males were (mmol/l): 5.81±0.06, 6.12±0.04 and 6.10±0.05 respectively, while in females 5.48±0.04, 5.56±0.02 and 5.77±0.01. Consequently, dyslipidemias were found in 70% of our group with T2DM of both sexes. They are induced by increase in non-HDL-C, correlate with degree of compensation of diabetes and with BMI. Therapeutic correction of dyslipidemias in patients with T2DM should be: normalization of glycemia and body weight. Screening for T2DM and its active treatment are most suitable method of secondary prevention of cardiovascular lesions caused by T2DM.